BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design [3]

Journal of Medicinal Chemistry

Volumn 43, Issue 19, 2000, Pages 3482-3486

  Babu, Y S ^a   Chand, P ^a   Bantia, S ^a   Kotian, P ^a   Dehghani, A ^a   El Kattan, Y ^a   Lin, T H ^a   Hutchison, T L ^a   Elliott, A J ^a   Parker, C D ^a   Ananth, S L ^a   Horn, L L ^a   Laver, G W ^a   Montgomery, J A ^a  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 ACETAMIDO 2 ETHYLBUTYL) 4C GUANIDINO 2 HYDROXYCYCLOPENTANE 1 CARBOXYLIC ACID; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ALPHA,BETA 6 ACETYL AMINO 3,6 DIDEOXYGLYCERO ALTRO 2 NONULOFURANOSONIC ACID; BCX 1812; CARBOXYLIC ACID; ETHYL 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; HEMAGGLUTININ; N ACETYL 2,3 DIDEHYDRO 2 DEOXYNEURAMINIC ACID; OSELTAMIVIR; SIALIC ACID DERIVATIVE; SIALIDASE; SIALIDASE INHIBITOR; TAMIFLU; UNCLASSIFIED DRUG; ZANAMIVIR;

CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HYDROGEN BOND; HYDROPHOBICITY; INFLUENZA; LETTER; STRUCTURE ACTIVITY RELATION; VIRUS PARTICLE;

ADMINISTRATION, ORAL; ANIMAL; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; CYCLOPENTANES; DRUG DESIGN; ENZYME INHIBITORS; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MICE; MODELS, MOLECULAR; NEURAMINIDASE; PROTEIN BINDING; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034699492     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0002679     Document Type: Letter

References (16)

1. Pandemic Influenza-confronting a reemergent threat
2. Serious morbidity and mortality associated with influenza epidemics
3. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine
4. Protection against lethal influenza with neuraminidase
5. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly or budding
6. Rational design of potent sialidase-based inhibitors of influenza virus replication
7. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity
8. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acid
9. Three-dimensional structure of influenza A N9 neuraminidase and its complex with inhibitor 2-deoxy-2,3-dehydro-N-acetyl-neuraminic acid
10. Uptake metabolism and excretion of orally administered double-labeled N-glycoloylneuraminic acid, single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat
11. Synthesis of sialic acid isomers with inhibitory activity against neuraminidase
12. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis
13. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of Influenza virus sialidases. 2. Crystallographic, molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B
14. Influenza virus neuraminidase inhibitors
15. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate